Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Healthcare Disparities | 4 | 2021 | 183 | 0.910 |
Why?
|
| European Continental Ancestry Group | 8 | 2017 | 1176 | 0.800 |
Why?
|
| Colorectal Neoplasms | 4 | 2017 | 232 | 0.750 |
Why?
|
| Adenocarcinoma | 10 | 2016 | 321 | 0.740 |
Why?
|
| African Americans | 8 | 2017 | 1435 | 0.660 |
Why?
|
| Pancreatic Neoplasms | 7 | 2016 | 135 | 0.610 |
Why?
|
| Colonoscopy | 1 | 2017 | 46 | 0.510 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 498 | 0.490 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 486 | 0.490 |
Why?
|
| Transsexualism | 1 | 2016 | 4 | 0.490 |
Why?
|
| Minority Health | 1 | 2016 | 9 | 0.480 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 104 | 0.480 |
Why?
|
| Health Status Disparities | 2 | 2021 | 138 | 0.480 |
Why?
|
| Minority Groups | 1 | 2016 | 90 | 0.460 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 455 | 0.440 |
Why?
|
| Rural Health | 1 | 2014 | 45 | 0.430 |
Why?
|
| Biomedical Research | 1 | 2016 | 186 | 0.420 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 176 | 0.420 |
Why?
|
| Common Bile Duct Neoplasms | 4 | 2016 | 6 | 0.410 |
Why?
|
| Ampulla of Vater | 4 | 2016 | 6 | 0.400 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 120 | 0.400 |
Why?
|
| Middle Aged | 30 | 2021 | 12726 | 0.380 |
Why?
|
| Oxidative Stress | 1 | 2014 | 265 | 0.370 |
Why?
|
| Aged | 25 | 2021 | 11022 | 0.360 |
Why?
|
| Gallbladder Neoplasms | 3 | 2021 | 35 | 0.350 |
Why?
|
| Prostatectomy | 5 | 2020 | 85 | 0.340 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2017 | 29 | 0.340 |
Why?
|
| Appendiceal Neoplasms | 3 | 2017 | 99 | 0.330 |
Why?
|
| Male | 30 | 2021 | 20740 | 0.330 |
Why?
|
| Humans | 37 | 2021 | 34562 | 0.320 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 19 | 0.310 |
Why?
|
| Drug Industry | 1 | 2009 | 18 | 0.310 |
Why?
|
| Commerce | 1 | 2009 | 70 | 0.290 |
Why?
|
| Female | 25 | 2021 | 21532 | 0.290 |
Why?
|
| Biological Products | 1 | 2009 | 80 | 0.280 |
Why?
|
| Bile Duct Neoplasms | 2 | 2018 | 33 | 0.270 |
Why?
|
| Blood Transfusion | 2 | 2017 | 76 | 0.250 |
Why?
|
| Mutation | 3 | 2017 | 532 | 0.240 |
Why?
|
| Adult | 18 | 2018 | 10030 | 0.240 |
Why?
|
| United States | 7 | 2021 | 4278 | 0.240 |
Why?
|
| Radiotherapy | 4 | 2020 | 92 | 0.240 |
Why?
|
| Carcinoid Tumor | 2 | 2016 | 13 | 0.240 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.230 |
Why?
|
| Dermatology | 2 | 2018 | 164 | 0.230 |
Why?
|
| Neuroendocrine Tumors | 2 | 2015 | 20 | 0.220 |
Why?
|
| DNA, Mitochondrial | 2 | 2015 | 34 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 197 | 0.220 |
Why?
|
| Adenoma | 2 | 2015 | 37 | 0.210 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 703 | 0.200 |
Why?
|
| Survival Rate | 9 | 2017 | 928 | 0.200 |
Why?
|
| SEER Program | 4 | 2017 | 38 | 0.200 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 4157 | 0.200 |
Why?
|
| Androgen Antagonists | 2 | 2020 | 20 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 804 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 2367 | 0.180 |
Why?
|
| Brachytherapy | 2 | 2020 | 31 | 0.180 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3825 | 0.170 |
Why?
|
| Cytodiagnosis | 2 | 2018 | 15 | 0.170 |
Why?
|
| Bile Ducts | 2 | 2018 | 20 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2021 | 3623 | 0.160 |
Why?
|
| Incidence | 3 | 2017 | 1290 | 0.150 |
Why?
|
| Prognosis | 7 | 2017 | 1606 | 0.150 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 55 | 0.140 |
Why?
|
| Registries | 2 | 2017 | 328 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 234 | 0.140 |
Why?
|
| Marital Status | 2 | 2016 | 22 | 0.140 |
Why?
|
| Air Ambulances | 1 | 2017 | 10 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2017 | 17 | 0.130 |
Why?
|
| Risk Factors | 4 | 2021 | 4137 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2017 | 33 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2017 | 18 | 0.130 |
Why?
|
| Pathology | 1 | 2017 | 21 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 24 | 0.130 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 30 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 44 | 0.130 |
Why?
|
| Resuscitation | 1 | 2017 | 69 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 614 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 6 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2017 | 109 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 36 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2017 | 148 | 0.120 |
Why?
|
| Critical Care | 1 | 2017 | 113 | 0.120 |
Why?
|
| Health Priorities | 1 | 2016 | 18 | 0.120 |
Why?
|
| Survivors | 1 | 2017 | 177 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2016 | 81 | 0.120 |
Why?
|
| Medicare | 1 | 2017 | 224 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 169 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 84 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 122 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 4 | 0.110 |
Why?
|
| Vitamins | 1 | 2015 | 75 | 0.110 |
Why?
|
| Electrons | 1 | 2015 | 12 | 0.110 |
Why?
|
| Mitotic Index | 1 | 2014 | 1 | 0.110 |
Why?
|
| Decision Making | 1 | 2017 | 203 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 34 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 196 | 0.110 |
Why?
|
| Georgia | 1 | 2014 | 14 | 0.110 |
Why?
|
| Isoprostanes | 1 | 2014 | 3 | 0.110 |
Why?
|
| beta Carotene | 1 | 2014 | 6 | 0.110 |
Why?
|
| Observer Variation | 3 | 2021 | 110 | 0.110 |
Why?
|
| Africa, Western | 1 | 2014 | 4 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2015 | 99 | 0.110 |
Why?
|
| Carotenoids | 1 | 2014 | 9 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2014 | 37 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2015 | 120 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 81 | 0.100 |
Why?
|
| Vitamin D | 1 | 2015 | 187 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2015 | 198 | 0.100 |
Why?
|
| Social Class | 1 | 2014 | 94 | 0.100 |
Why?
|
| Age Factors | 5 | 2017 | 1262 | 0.100 |
Why?
|
| Age Distribution | 1 | 2014 | 211 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2020 | 2463 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 122 | 0.100 |
Why?
|
| Calcium | 1 | 2015 | 343 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 431 | 0.100 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2012 | 2 | 0.090 |
Why?
|
| Gallbladder | 1 | 2012 | 4 | 0.090 |
Why?
|
| Polyps | 1 | 2012 | 9 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 596 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 225 | 0.090 |
Why?
|
| Diet | 1 | 2014 | 418 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 600 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 823 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 16 | 0.080 |
Why?
|
| Hispanic Americans | 1 | 2016 | 948 | 0.080 |
Why?
|
| Mucins | 3 | 2016 | 18 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2009 | 15 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1607 | 0.080 |
Why?
|
| Neoplasms | 1 | 2017 | 793 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 176 | 0.080 |
Why?
|
| Young Adult | 4 | 2018 | 2831 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 939 | 0.070 |
Why?
|
| Disease Progression | 3 | 2017 | 634 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2020 | 22 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 189 | 0.070 |
Why?
|
| Urinary Incontinence | 2 | 2020 | 68 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2017 | 1910 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 142 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 590 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 354 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 808 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 510 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2004 | 6 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2004 | 15 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 2353 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 1508 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 402 | 0.040 |
Why?
|
| Chile | 1 | 2021 | 7 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 12 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 245 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 3805 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 6 | 0.030 |
Why?
|
| Appendectomy | 1 | 2017 | 19 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 30 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 16 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2017 | 11 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 15 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 37 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 18 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2017 | 24 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 30 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 27 | 0.030 |
Why?
|
| Military Medicine | 1 | 2017 | 26 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 51 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2017 | 57 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 63 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 86 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2017 | 113 | 0.030 |
Why?
|
| Emotions | 1 | 2017 | 60 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2017 | 88 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 1079 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 94 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 30 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 305 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 98 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 54 | 0.030 |
Why?
|
| Urination | 1 | 2016 | 69 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 157 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 480 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 341 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 206 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 129 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2015 | 5 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 19 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 97 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 170 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 71 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2015 | 12 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 51 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2015 | 12 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 98 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 325 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 265 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 318 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 389 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 803 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 597 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 380 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 297 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 708 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 657 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 544 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 260 | 0.020 |
Why?
|
| Mucin-2 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mucin-6 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Keratin-7 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 21 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 71 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 55 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 628 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1032 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 24 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 26 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 485 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2009 | 33 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 806 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2614 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 8 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 204 | 0.010 |
Why?
|